Johnson & Johnson's Long-Acting HIV-1 Therapy Receives Approval in China

Oct 25, 2023 11:46 CST Updated 11:46

Xian Janssen

Pharmaceutical R&D and Manufacturer

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

After 4 years of refinement, the largest IP in China's oncolytic virus field is重磅来袭!

COVC 2023 The 4th Oncolytic Virus Drug Development ConferenceHand in Hand30+Top global scientists in oncolytic virus drug development1000+From core professionals of oncolytic virus enterprises and upstream/downstream industries,November 17-18See you in Shanghai!

Source: PharmaCube

On October 24, the official website of the National Medical Products Administration (NMPA) announced that Johnson & Johnson's Rilpivirine Injection (brand name: Rekambys) has been approved for marketing in China to treat HIV-1 infection. Previously, in December 2012, the Rilpivirine tablet was already launched in China.

Rilpivirine Injection is a long-acting injectable suspension, which was approved by the FDA in January 2021 for use in combination with Cabotegravir Injection for specific adult patients infected with HIV-1, under the brand name Cabenuva. Cabotegravir, when used together with Rilpivirine, can be administered once a month or every two months as an alternative to traditional antiviral therapy for patients whose virus has been suppressed and stabilized.

Cabotegravir is an HIV integrase strand transfer inhibitor (INSTI), initially developed by Shionogi, with the long-acting injectable formulation developed by ViiV Healthcare, a subsidiary of GSK. In July this year, the marketing application for cabotegravir injection was approved by the regulatory authority.

Financial reports show that the long-acting antiviral therapy Cabenuva, composed of Rilpivirine Injection and Cabotegravir Injection, achieved sales of $422 million in 2022, with sales reaching $374 million in the first half of this year.

Disclaimer:

The content of the article is for reference only and does not constitute investment advice. Investors who take action based on this information bear their own risks. The article maintains a neutral stance regarding statements and viewpoints, and does not provide any express or implied guarantees concerning the accuracy, reliability, or completeness of the content. Readers are advised to use the information as a reference only and assume full responsibility for their actions. Articles published by this official account focus on sharing; if there are any infringements, please contact us, and we will remove them.

Contact Us

Registration is about to close.

Scan to consult immediately

咨询通道-truesaw.png

Phone: 13816031174 (Same as WeChat)

Click here "Read More" to enter the registration and participation channel